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Abstract 
BACKGROUND: Psoriasis is a chronic, recurrent inflammatory skin disease. It is characterised by autoimmune, 
environmental factors and complex genetic disorder.  
AIM: To explore the role of IL-6, IL-8, and ACE I/D polymorphism in the pathogenesis of Psoriasis and 
investigation of the relationship between ACE polymorphism and occurrence of psoriasis.  
PATIENTS AND METHODS: In this study, we took 73 psoriasis patients and 47 healthy patients as a control. 
These two groups subjected to analysis for ACE gene I/D polymorphism by PCR and biochemical methods.  
RESULTS: The serum levels of ACE, IL-8 and IL-6 were statistically significantly higher in psoriasis patients 
compared to healthy subjects (P < 0.001). ID and DD polymorphism were more common in psoriasis patients than 
healthy subjects. Also, D allele was significantly over-represented in patients compared to controls (52.7% Vs 
35.1%).  
CONCLUSION: ACE gene polymorphism might grant susceptibility to develop psoriasis. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Psoriasis is a chronic, recurrent inflammatory 
skin disease that can have a great effect on a 
patient’s self-esteem [1]. It is affected by autoimmune, 
environmental factors and complex genetic disorder 
[2]. The effect of the disease is not only limited solely 
to the skin but also causes permanent joint damage in 
nearly 30% of the patients [3]. 
Angiotensin-converting enzyme (ACE) is a 
zinc metallopeptidase, located on chromosome 
17q23. It contains an insertion (I)/deletion (D) 
polymorphism within intron 16 that contain the most 
genetic variables of the variability of serum ACE 
activity and is associated with the development of 
psoriasis [4].  
Several studies indicated that Angiotensin-
converting enzyme is a major and effective factor in 
creating angiotensin II (Ang II) and inactivating 
bradykinin [5] [6].  
Active angiotensin II increases the production 
of reactive oxygen species (ROS) and the synthesis of 
cytokines such as interleukin-6 (IL-6) and IL-8 which 
play an important role in the development of psoriasis 
[7]. Also, inactivation of bradykinin by ACE stimulates 
the synthesis of cytokines such as IL-6, IL-8 and nitric 
oxide (NO) [8] [9] [10].  
 Abd Elneam et al. Angiotensin-Converting Enzyme (ACE ) D Allele as a Risk Factor 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2018 May 20; 6(5):772-776.                                                                                                                                                       773 
 
Interleukin 6 (IL-6) is a major inducer of 
regulated expression of many cytokines [11]. IL-6 is 
one of the normal skin components, and it was 
immunologically founded in endothelial cells, 
keratinocytes, and ﬁbroblasts [11]. IL-6 has been 
suggested to function as an autocrine mitogen in the 
psoriatic epidermis [12]. 
Interleukin 8 (IL-8) is one of the most common 
chemokines that is elevated in the psoriatic lesion 
[13]. Moreover, both mRNA and peptide IL-8 have 
been detected in situ in psoriatic patients [14]. 
Elevated IL-8 blood levels are considered as a marker 
for the systemic inflammatory disorders [15]. 
Our main goal was to explore the role of IL-6, 
IL-8, and ACE I/D polymorphism in the pathogenesis 
of Psoriasis. Also, our specific aim is to investigate the 
relationship between ACE polymorphism and 
occurrence of psoriasis. 
 
 
Subject and Methods 
 
The present study was performed at 
Outpatient Dermatology Clinic, Buraidah Central 
Hospital, Qassim region, Saudi Arabia between 
October 2016 and May 2017.  
A total of 73 patients (42 male and 31 
females) were enrolled for this case-control study. The 
diagnosis was established by clinically-physical 
examination as the diagnosis was striated forward (All 
patients had characteristic erythematosquamous 
plaques located on the trunk and limbs). Patients had 
an only cutaneous form of psoriasis, with no systemic 
involvements were included in the study. None of the 
patients had received any systemic 
immunosuppressive medications or used any local 
treatment at the site of biopsies for 4 weeks before 
study participation. 
Patients were classified according to body 
surface area (BSA) into severe psoriasis vulgaris 
greater than 10% of the body surface, moderate 
psoriasis vulgaris 5%-10% of the body surface and 
mild psoriasis vulgaris less than 5% of the body 
surface [16]. 
The other 47 subjects were healthy volunteers 
who were age and gender-matched with the psoriasis 
group (27 male and 20 females), they had no clinical 
evidence or family history of psoriasis or any other 
autoimmune disorder.  
Both groups had undergone complete 
physical and clinical examinations, genetics studies 
and biochemical tests. 
Before the initiation of the study, informed 
consent was obtained from all individuals chosen for 
the study. The aim and the value of the work were 
explained to them in a simplified manner. This study 
was approved by the Local Medical Ethical Committee 
and according to their instructions.  
Serum ACE concentrations were measured, 
utilising the Human ACE Quantikine ELISA Kit from 
R&D Biotech brand system [17]. 
The interleukin-6 level was determined using 
a commercially available ELISA kit (Quantikine, 
human IL-6R & D Systems, Minneapolis, USA) by the 
manufacturer’s instructions [18]. 
Serum IL-8 samples from all patients were 
tested in a sandwich ELISA using according to the 
manufacturers' instructions (R&D, Minneapolis, USA; 
Bender, Vienna; Amersham, Germany) [19]. 
Blood samples were collected on Na2EDTA 
as an anticoagulant. Genomic DNA was purified from 
200 μl whole blood with the QIAamp® DNA BloodMini 
Kit according to manufacture instruction for Blood 
protocol. 
To determine the ACE gene I/D 
polymorphism, a genomic DNA fragment on intron 16 
of the ACE gene was amplified by using Polymerase 
Chain Reaction (PCR) method with a pair of 
oligonucleotide primers: The upstream of primer 
sequence was: 5`-CTG GAG ACC ACT CCC ATC 
CTT TCT -3` and the downstream was: 5`- GAT GTG 
GCC ATC ACA TTC GTC AGA T -3` (20). The 
primers were blasted to the gene bank database 
https://blast.ncbi.nlm.nih.gov/Blast.cgi [21].  
Data was presented by means ± SD and 
percentages. The compiled data were computerised 
and analysed by SPSS PC+, version 12. The following 
tests of significance were used: Analysis of variance 
(ANOVA) test between more than two means, t-test 
between means we used to analyse the mean 
difference, t-test between percentage to analyse 
percent difference and chi-square. A level of 
significance with p ≤ 0.001 was considered highly 
significant and p ˃ 0.05 was considered insignificant. 
 
 
Results  
 
In our present study, we analysed ACE gene 
polymorphism for Seventy–three (42 male and 31 
females) psoriasis patients and Forty –seven (27 male 
and 20 females) healthy controls they had no clinical 
evidence or family history of psoriasis or of any other 
autoimmune disorder. Clinical and General Data of all 
the patients and controls are shown in Table 1. It was 
noted that serum ACE, serum IL-8 and serum IL-6 
were statistically significantly higher in psoriasis 
patients than in healthy subjects (P < 0.001). 
Clinical presentation of psoriasis showed that 
23 patients (31.5%) have severe psoriasis vulgaris, 26 
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patients (33.5%) have moderate psoriasis vulgaris 
and 24 patients (33%) have mild psoriasis. 
Table 1: General and laboratory characteristics of psoriatic 
patients and healthy control 
 
Parameters 
Patients N ( 73) 
Mean ± SD 
Control N (47) 
Mean ± SD 
P-value 
Age/years (Mean ± SD) 41.2 ± 4.8 38.1 ± 6.8 0.411 
Male/Female (N, %) 42(57.5%)/31(42.5%) 27(57.4%)/20(42.6%) 0.442 
Severe psoriasis vulgaris (N, %) 23 (31.5%)   
Moderate psoriasis vulgaris (N, %) 26 (33.5%)   
Mild psoriasis vulgaris (N, %) 24 (33%)   
Presence of Family history (N, %) 46/63%   
Absent of Family history (N, %) 27/37%   
Serum ACE (IU/L) 21.7 ± 5.5 7.7 ± 4.1 <0.001* 
Serum IL-6 (pg/ml) 17.5 ± 0.48 8.9 ± 0.60 <0.001* 
Serum IL-8 (pg/ml) 15.9 ± 0.9 7.6 ± 1.5 <0.001* 
SD, standard deviation; ACE, angiotensin-converting enzyme; IL-6, interleukin-6; IL-8, 
interleukin-8; N, Number; *Significance between healthy Subjects and psoriatic patients 
(P˂0.05). 
 
Comparison of ACE genotypes in patients 
and controls showed that I/D were the most common 
(45.2%) followed by D/D (30.1%) then I/I (24.7%). I/I 
was the most common in healthy subjects (46.8%) 
while I/D and D/D genotypes were found to be 36.2% 
and 17% respectively (Table 2). 
Table 2: Comparison of ACE genotype in psoriatic patients and 
healthy control 
Genotypes Patients (N,%) Control (N,%) P-Value 
I/ I 18 (24.7 %) 22 (46.8%) 0.007* 
I/D 33 ( 45.2 %) 17 (36.2%) 0.872 
D/D 22 ( 30.1 % ) 8 (17 %) 0.001* 
N, number; *p value<0.05 is statistically significant. 
 
The allele frequency was significantly different 
between patients and controls (P = 0.005). The results 
indicated that the D allele was significantly over-
represented in patients compared to the controls 
(52.7% vs 35.1 %) (Table 3).  
Table 3: Comparison of allele frequency in psoriatic patients 
and healthy control 
Alleles frequency  Patients (N, %) Control (N, %) P-Value  
I 69 (47. 3%) 61 (64.9 %) 0.005 
D 77 (52.7 %)  33 (35.1%)  0.002 
N, number; *p value<0.05 is statistically significant. 
 
Patients with DD genotypes have statistically 
significantly higher levels of serum ACE (P < 0.001), 
higher serum IL-8 (P < 0.001) and higher serum IL-6 
(P < 0.001), Table 4. 
Table 4: Comparison of biochemical parameters and ACE 
genotypes in psoriatic patients 
Parameters I/ I (n = 18) I/D (n = 33) D/D (n = 22) P-value 
Serum ACE (IU/L) 16.88 ± 4.22 23.66 ± 1.66 28.07 ± 3.21 0.001* 
Serum IL-6 (pg/ml) 23.67 ± 2.9 39.24 ± 1.54 47.22 ± 2.5 0.001* 
Serum IL-8 (pg/ml) 12.66 ± 2.3 18.34 ± 1.6 28.32 ± 4.1 0.001* 
SD, standard deviation; ACE, angiotensin-converting enzyme; IL-6, interleukin-6; IL-8 
interleukin - 8; N, Number; * Significance between healthy Subjects and psoriatic patients 
(P ˂ 0.05). 
 
 
Comparison of biochemical parameters and 
variable clinical types of psoriasis indicated that the 
levels of serum ACE, serum IL-6, and IL-8 higher in 
Severe psoriasis vulgaris patients than in those with 
Moderate psoriasis and Mild psoriasis vulgaris with P-
values 0.012, 0.001 and 0.008 respectively (Table 5). 
Table 5: Comparison of biochemical parameters and variable 
clinical types of psoriasis in our patients  
P-value 
Mild psoriasis 
vulgaris (N = 24) 
Moderate psoriasis 
vulgaris (N = 26) 
Severe psoriasis 
vulgaris (N = 23) 
Parameters 
0.012* 14.79 ± 2.7 18.9 ± 2.88 23.25 ± 1.21 Serum ACE (IU/L) 
0.001* 17.44 ± 2.55 21.56 ± 3.9 38.5 ± 4.5 Serum IL-6 (pg/ml) 
0.008* 11.23 ± 1.3 14.99 ± 2.88 22.3 ± 3.8 Serum IL-8 (pg/ml) 
SD, standard deviation; ACE, angiotensin-converting enzyme; IL-6, interleukin-6; IL-8 
interleukin -8; N, Number; * Significance between healthy Subjects and psoriatic patients 
(P ˂ 0.05). 
 
 Our results showed that D/D genotype was 
more common with severe psoriasis vulgaris (52.2%). 
On the other side, I/D was more frequent in Moderate 
psoriasis vulgaris and Mild psoriasis vulgaris patients 
(50% and 58.3% respectively) (Table 6). 
Table 6: Comparison of ACE genotypes and variable clinical 
types of psoriasis in our patients 
 Parameters I/I (N, %) I/D (N, %) D/D (N, %) P-value 
Severe psoriasis vulgaris (N = 23) 5 (21.7%) 6 (26.1 %) 12 (52.2 %) 0.001* 
Moderate psoriasis vulgaris (N = 26) 6 (23.1%) 13 (50%) 7 (26.9%) 0.001* 
Mild psoriasis vulgaris (N = 24) 7(29.1%) 14 (58.3%) 3 (12.6%) 0.001* 
*Significance between healthy Subjects and psoriatic patients (P ˂ 0.05). 
 
 
Discussion 
 
The present study provides a relationship 
between ACE I/D polymorphism, IL-6, IL-8 and 
psoriasis as a risk factor was determined. 
Our results indicated that psoriasis patients 
have serum IL-6 and serums IL-8 were significantly 
higher than in controls (P < 0.001). Our results are in 
line with several studies [22] [23] [24] they reported 
that elevated levels of serum IL-6 and serum IL-8 in 
psoriasis vulgaris patients. 
The results of the current study indicated that 
the ACE polymorphism of the I/I genotype was more 
frequent in controls (46.8%) than in psoriasis patients 
(24.7%), while the I/D and the D/D genotypes were 
more abundant in psoriasis vulgaris patients (45.2% 
and 30.1% respectively). However, this difference was 
statistically not highly significant, and this can be 
explained by the small sample size of our study. Also, 
we observed that DD genotype was more common in 
patients with severe psoriasis vulgaris (52.2%) than 
those with intermediate (26.9%) and mild (12.6%) 
disease. These results are consistent with Song et al., 
2015 who revealed that frequency of DD and ID in 
case more than II [25]. 
Our results revealed that D allele was 
significantly higher in the psoriasis patients (52.7%) 
than in controls (35.1%). These results were 
consistent with Min Huang et al., 2017. Who found 
that the D allele was frequency higher in psoriasis 
patients than in the controls (43.8% and 31.8% 
respectively) [26]. 
Multiple studies have been performed to 
detect the polymorphisms as an important factor in the 
development of psoriasis: TNF α gene -238G/A 
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polymorphism [27] -2518 A/G MCP-1 and -403 G/A 
RANTES promoter gene polymorphisms [28], 
CARD14 rs11652075 polymorphism [29] and support 
the genetic hypothesis in psoriasis.  
Our findings showed that a significant 
relationship between the serum ACE levels in patients 
and healthy subjects (P < 0.001). Moreover, we 
showed a significant difference of the serum ACE 
levels with the different ACE genotypes; psoriasis 
patients with ACE DD genotype showed the highest 
mean ACE serum level (28.07 ± 3.21), while patients 
with ACE II genotype had the lowest mean serum 
ACE level (16.88 ± 4.22). In the present study, we 
observed that DD was associated with increased 
levels of IL-6 and IL-8 (47.22 ± 2.5 and 28.32 ± 4.1 
respectively). Also, comparison of biochemical 
parameters and variable clinical types of psoriasis in 
our patients showed increased levels of all variables 
in patients with severe psoriasis vulgaris compared to 
those with Moderate psoriasis vulgaris and mild 
psoriasis vulgaris. 
Increased levels of serum ACE, IL-6 and IL-8 
in psoriasis patients were due to the important role of 
ACE in inflammation. Where ACE converts Ang I into 
Ang II and inactivates bradykinin [30]. Ang II activates 
cytokines like IL-6 and IL-8, thus exerting 
proinflammatory effects [6]. This indicates an 
important role of ACE in the pathogenesis of psoriasis 
[31]. 
In conclusion, ACE gene polymorphism might 
confer susceptibility to the development psoriasis.  
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